Core Viewpoint - Thermo Fisher Scientific Inc. has priced an offering of €2.1 billion in euro-denominated senior notes, which will be issued by its wholly-owned finance subsidiary, with the offering expected to close around December 1, 2025 [1][2]. Offering Details - The offering includes €1 billion of floating rate senior notes due 2027 and €1.1 billion of fixed rate senior notes with a 3.628% interest rate due 2035, both at an issue price of 100% of their principal amount [7]. - The notes will be fully and unconditionally guaranteed by Thermo Fisher, with interest payments structured as quarterly for floating rate notes and annually for fixed rate notes [1][2]. Use of Proceeds - The net proceeds from the sale of the notes will be utilized for general corporate purposes, which may encompass acquisitions, debt repayment, working capital, capital expenditures, or repurchase of outstanding equity securities [2]. Management and Regulatory Information - The joint book-running managers for the offering are Barclays Bank PLC, BNP PARIBAS, HSBC Continental Europe, and Morgan Stanley & Co. International plc [3]. - The offering is being made under an effective registration statement filed with the U.S. Securities and Exchange Commission (SEC) [4]. Company Overview - Thermo Fisher Scientific Inc. is a leading company in the science sector, with annual revenues exceeding $40 billion, and is dedicated to enabling customers to improve health, safety, and productivity [9].

Core Insights - Thermo Fisher Scientific has received FDA approval for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic for identifying patients eligible for treatment with Bayer's new HER2-directed therapy, HYRNUO™ (sevabertinib) [1] Company Summary - The Ion Torrent™ Oncomine™ Dx Target Test is designed to assist clinicians and pathologists in identifying non-small cell lung cancer (NSCLC) tumors [1]